2335 — Shaanxi Micot Pharmaceutical Technology Share Price
Last trade - 00:00- HK$7.96bn
- HK$6.58bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.18 | ||
| Price to Tang. Book | 7.18 | ||
| Price to Free Cashflow | 672.73 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.41% | ||
| Return on Equity | -77.1% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Shaanxi Micot Pharmaceutical Technology Co Ltd is a China-based company principally engaged in the discovery, development and commercialization of bi-/multi-specific peptide drugs. The Company’s main products are used for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases. The Company has developed a pipeline of bi-/multi-functional peptides and innovative drug candidates, including MT1013 product, a peptide drug targeting both calcium-sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptors, primarily developed for the treatment of chronic kidney disease-secondary hyperparathyroidism (CKD-SHPT), with the potential to be further developed for additional indications such as the coexistence of chronic kidney disease, mineral and bone disorder (CKD-MBD) with osteoporosis and CKD-SHPT not on dialysis; and XTL6001, MT1002 and MT200605.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 19th, 2007
- Public Since
- June 24th, 2026
- No. of Employees
- 153
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 331,740,350
- Address
- XI'AN, 710075
- Web
- https://www.micot.cn
- Phone
- +86 2989303986
- Auditors
- Deloitte Touche Tohmatsu
Latest News for 2335
Similar to 2335
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 04:05 UTC, shares in Shaanxi Micot Pharmaceutical Technology are trading at HK$24.00. This share price information is delayed by 15 minutes.
Shares in Shaanxi Micot Pharmaceutical Technology last closed at HK$24.00 and the price had moved by over the past 365 days. In terms of relative price strength the Shaanxi Micot Pharmaceutical Technology share price has matched the FTSE Developed Asia Pacific Index by over the past year.
The overall consensus recommendation for Shaanxi Micot Pharmaceutical Technology is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreShaanxi Micot Pharmaceutical Technology does not currently pay a dividend.
Shaanxi Micot Pharmaceutical Technology does not currently pay a dividend.
Shaanxi Micot Pharmaceutical Technology does not currently pay a dividend.
To buy shares in Shaanxi Micot Pharmaceutical Technology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$24.00, shares in Shaanxi Micot Pharmaceutical Technology had a market capitalisation of HK$7.96bn.
Here are the trading details for Shaanxi Micot Pharmaceutical Technology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2335
Based on an overall assessment of its quality, value and momentum Shaanxi Micot Pharmaceutical Technology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Shaanxi Micot Pharmaceutical Technology is HK$38.01. That is 58.39% above the last closing price of HK$24.00.
Analysts covering Shaanxi Micot Pharmaceutical Technology currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.96 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shaanxi Micot Pharmaceutical Technology. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$24.00, shares in Shaanxi Micot Pharmaceutical Technology were trading -17.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shaanxi Micot Pharmaceutical Technology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$24.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Shaanxi Micot Pharmaceutical Technology's directors